Since established in 2019，Juncell Therapeutics stick to our mission of “rebuild cells, rescue lives” and the vision of “create miracles with tehnology”. We pride ourselves in the values of “focus, innovation, inclusiveness, sharing”, attained several milestones during the company development。

2019

Jun   Company establishment

2020

Feb   Receiving Pre-A funding at a level of tens of millions RMB

Jun   Inauguration of the R&D laboratory and office

Dec  Operating the GMP workshops

2021

Jan   Enrolling the first patient in the IIT of GC101

Feb   Receiving Series A funding at a level of nearly 100 million RMB

Jul    Achieving the first CR in the IIT of GC101

Aug   Establishing the Viable Cell Bank

Sep   Receiving Series A+ funding at a level of tens of millions RMB

Sep   Submitting pre-IND meeting application for GC101

Dec   Receiving Series A++ funding at a level of nearly 100 million RMB

Dec   Granted the National High-Tech Enterprise

2022

Jan   Submitting the IND application dossier of GC101 to CDE

Feb   CDE accepts the IND application for GC101

Apr   IND application for GC101 approved by NMPA  

Aug   Initiating the Phase I clinical trial of GC101

2023

Feb   Winning the highest award in the National Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology

Mar   Granted the title of Shanghai Specialized and Innovative Enterprises

Jun   Enrolling the first patient in the IIT of GC203

Aug   Achieving the first PR in the IIT of GC203

2024

Jan   Receiving Series B1 funding at a level of nearly 100 millions RMB

Feb   CDE accepts the IND application for GC203

Apr   IND application for GC203 approved by NMPA

May  Initiating the Phase I clinical trial of GC203

Jun   Receiving Series B2 funding at a level of nearly 300 millions RMB